Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.26

€0.26

-6.880%
-0.019
-6.880%
-

-

 
10:41 / Tradegate WKN: A3D1K3 / Name: Bionxt Solutions / Stock / Small Cap /

Bionxt Solutions Inc. Stock

Heavy losses for Bionxt Solutions Inc. today as the stock fell by -€0.019 (-6.880%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Bionxt Solutions Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Bionxt Solutions Inc. in the next few years

Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps

VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that based on the recent success of its

BioNxt Reports Successful Results From ODF Cladribine PK Study
BioNxt Reports Successful Results From ODF Cladribine PK Study

VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic

BioNxt Reports Completion of ODF Cladribine PK Study
BioNxt Reports Completion of ODF Cladribine PK Study

VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic